The provision of a pharmaceutical composition for treating an autoimmunedisease comprising a pharmaceuticallyacceptable carrier and an agent capable of activating CD4+CD25+ regulatory Tcells, wherein the composition is to beadministered to a subject in a dose of the agent from 10 mg to 200 mg.